{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [
    "School of Public Health, Nanjing Medical University, Nanjing, P.R. China",
    "Medical Research Department, Qilu Pharmaceuticals, Global Research and Development of Innovative Medicine, Shanghai, P.R. China",
    "Liver Cancer Research Institute, Shanghai Zhongshan Hospital Affiliated to Fudan University, Shanghai, P.R. China",
    "TsientTang Institute for Advanced Study, Hangzhou, P.R. China"
  ],
  "article_type": "methods article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Fan Yang"
    },
    {
      "affs": [
        1
      ],
      "name": "Weikang Tao"
    },
    {
      "affs": [
        0
      ],
      "name": "Zihang Zhong"
    },
    {
      "affs": [
        2
      ],
      "name": "Jia Fan"
    },
    {
      "affs": [
        0
      ],
      "name": "Hao Yu"
    },
    {
      "affs": [
        0,
        3
      ],
      "name": "Shukui Qin"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/f4r679w6fq13a.bib",
  "cited_by": 0,
  "doi": "10.1080/14796694.2026.2739789",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13733572/",
  "id": "f4r679w6fq13a",
  "issns": [
    "1479-6694",
    "1744-8301"
  ],
  "landing_url": "https://doi.org/10.1080/14796694.2026.2739789",
  "language": "en",
  "licence": "unknown",
  "licence_label": "Licence not stated",
  "licence_source": "unknown",
  "licence_url": null,
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Clinical Trial Protocol"
    ],
    [
      "heading",
      "Method"
    ],
    [
      "openalex",
      "2721|Hepatocellular Carcinoma Treatment and Prognosis"
    ]
  ],
  "openalex": "W7215114678",
  "pdf_url": null,
  "pmcid": "PMC13733572",
  "pmid": "42820658",
  "published": "2026-10-01",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/f4r679w6fq13a.ris",
  "sources": [
    {
      "first_seen": "2026-11-08T12:23:19Z",
      "native_id": "PMC13733572",
      "source": "pmc",
      "url": "https://doi.org/10.1080/14796694.2026.2739789"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2721|Hepatocellular Carcinoma Treatment and Prognosis",
      "subfield": "general"
    }
  ],
  "title": "DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma",
  "title_text": "DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T12:23:19Z",
  "url": "https://research.draconitic.com/paper/f4r679w6fq13a",
  "venue": "Future Oncology",
  "versions": []
}